SEC Company Response from SciSparc Ltd. (SPRC) (CIK 0001611746) (SPRC) — Dec 16, 2016
SciSparc Ltd. (SPRC) (CIK 0001611746)
Date: Dec. 16, 2016 · CIK: 0001611746 · Accession: 0001213900-16-019477
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214458
Letter
Re: THERAPIX BIOSCIENCES LTD.
December 16, 2016
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, DC 20549
Registration Statement on Form F-1 (Registration No. 333-214458)
Concurrence in Acceleration Request
Ladies and Gentlemen:
H.C. Wainwright & Co., LLC (“Wainwright”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Therapix Biosciences Ltd. that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on December 20, 2016, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
H.C. WAINWRIGHT & CO., LLC
Show Raw Text
CORRESP
1
filename1.htm
December
16, 2016
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Washington,
DC 20549
Re:
THERAPIX
BIOSCIENCES LTD.
Registration Statement
on Form F-1 (Registration No. 333-214458)
Concurrence in
Acceleration Request
Ladies
and Gentlemen:
H.C.
Wainwright & Co., LLC (“Wainwright”), as representative of the underwriters for the referenced offering,
hereby concurs in the request by Therapix Biosciences Ltd. that the effective date of the above-referenced registration statement
be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on December 20, 2016, pursuant to Rule 461 under
the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
H.C. WAINWRIGHT & CO., LLC
By:
/s/
Mark W. Viklund
Name:
Mark W. Viklund
Title: Chief Executive Officer